Women's Health Initiative estrogen plus progestin clinical trial: A study that does not allow establishing relevant clinical risks
Artículo
![Thumbnail](/themes/Mirage2/images/cubierta.jpg)
Open/ Download
Publication date
2015Metadata
Show full item record
Cómo citar
Aedo Monsalve, Sócrates
Cómo citar
Women's Health Initiative estrogen plus progestin clinical trial: A study that does not allow establishing relevant clinical risks
Author
Abstract
© 2015 by The North American Menopause Society. Objective: This study aims to determine time differences (differences in restricted mean survival times [RMSTs]) in the onset of invasive breast cancer, coronary heart disease, stroke, pulmonary embolism, colorectal cancer, and hip fracture between the placebo group and the conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg group of the Women's Health Initiative (WHI) trial based on survival curves of the original report and to provide adequate interpretation of the clinical effects of a given intervention. Methods: Distribution of survival function was obtained from cumulative hazard plots of the WHI report; Monte Carlo simulation was performed to obtain censored observations for each outcome, in which assumptions of the Cox model were evaluated once corresponding hazard ratios had been estimated. Using estimation methods such as numerical integration, pseudovalues, and flexible parametric modeling, we determine
Indexation
Artículo de publicación SCOPUS
Identifier
URI: https://repositorio.uchile.cl/handle/2250/166680
DOI: 10.1097/GME.0000000000000472
ISSN: 15300374
10723714
Quote Item
Menopause, Volumen 22, Issue 12, 2018, Pages 1317-1322
Collections